MedPath

A multicenter, double-blind, placebo-controlled phase II study of apreipitant for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC) in women younger than 70 years without alcohol drinking habit

Phase 2
Conditions
Female cancer patients younger than 70 years without alcohol drinking habit
Registration Number
JPRN-UMIN000004998
Lead Sponsor
Hanshin Cancer Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
94
Inclusion Criteria

Not provided

Exclusion Criteria

Any anthracylin and cyclophosphamide (AC) regimens are not permitted.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath